22q11.2 Deletion Syndrome Financial Planning: SNT Design, the Schizophrenia Watch, and the GINA Insurance Problem

22q11.2 deletion syndrome — also called DiGeorge syndrome, velocardiofacial syndrome, or conotruncal anomaly face syndrome — is the second most common chromosomal disorder in humans after Down syndrome, yet it remains widely underrecognized in financial and legal planning circles. The financial planning profile of 22q11.2 DS is unlike any other condition in the special needs space: a child who may function independently as a young adult can, in 25 to 30 percent of cases, develop schizophrenia in early adulthood — requiring a complete restructuring of the financial plan at a moment when the family may have already scaled back planning efforts. The SNT, ABLE account, and estate plan that fit a moderately learning-disabled but employed 25-year-old may be entirely inadequate for a 32-year-old who has just received a first-episode psychosis diagnosis. Building the plan to handle both trajectories from the beginning is not pessimism — it is the correct reading of the statistical risk.

Who this affects: prevalence and profile

22q11.2 deletion syndrome occurs in approximately 1 in 4,000 live births, making it the most common microdeletion syndrome and second only to trisomy 21 (Down syndrome) among chromosomal disorders.¹ The syndrome is caused by a small deletion of genetic material from the long arm of chromosome 22, at band q11.2. The deletion disrupts approximately 30 to 40 genes and produces a wide spectrum of clinical effects, most commonly including:

• Congenital heart disease in approximately 75% of cases — predominantly conotruncal defects including tetralogy of Fallot (approximately 20%), ventricular septal defect (14%), interrupted aortic arch (10%), truncus arteriosus (9%), and pulmonary atresia with VSD (9%)⁷
• Palatal abnormalities in approximately 70–75%, including velopharyngeal insufficiency (VPI), submucous cleft palate, and overt cleft palate — causing hypernasality, speech delay, and feeding difficulties
• T-cell immune deficiency from thymic hypoplasia, ranging from mild (most individuals) to complete absence of T-cells requiring IVIG or bone marrow transplant (approximately 1–2%)
• Hypocalcemia from parathyroid hypoplasia or hypoplasia, requiring lifelong calcium and vitamin D supplementation in many individuals
• Learning disabilities in nearly all individuals, with average IQ approximately 70 and a range of 55 to 85; formal intellectual disability (IQ below 70) is present in roughly 40% of individuals²
• Psychiatric disorders in approximately 60% of adults, including anxiety disorders, depression, ADHD, and most significantly, schizophrenia in 25–30% of individuals by midlife³

Life expectancy for individuals with 22q11.2 DS who receive appropriate cardiac care is near-normal for the majority — creating a planning horizon of 50 to 70 years from birth. The wide clinical variability means that some children with 22q11.2 DS will graduate from college and work full careers, while others will require lifelong supported living. Planning must account for both the functioning trajectory and the psychiatric risk.

The schizophrenia watch: planning for a psychiatric turn

No other genetic condition carries schizophrenia risk comparable to 22q11.2 deletion syndrome. Research estimates that 25% to 53% of individuals with 22q11.2 DS will develop schizophrenia or a related psychotic disorder during their lifetime — compared with approximately 1% in the general population.³ More conservative estimates center around 25 to 30 percent; the range reflects differences in diagnostic methods and follow-up length across studies. The onset typically occurs in late adolescence or early adulthood, with peak risk in the 20s and 30s.

The financial planning implication is critical: a family whose child has a 22q11.2 diagnosis cannot treat the schizophrenia risk as an unlikely contingency that would require separate planning later. The SNT and estate plan must be structured from the beginning to handle the psychiatric trajectory without requiring an emergency amendment at the moment of psychosis onset — when decision-making capacity may be reduced and family resources are already strained.

What changes when schizophrenia develops

For a 22q11.2 adult who has been working and managing finances independently, first-episode psychosis typically triggers several simultaneous planning changes:

• SSI and Medicaid eligibility. If the individual was not enrolled in SSI before schizophrenia onset, applying at that point is possible but requires documentation of the disability's functional impact. Schizophrenia in the context of 22q11.2 DS qualifies under Blue Book Listing 12.03 (schizophrenia spectrum) if it causes marked limitations in cognitive, social, or adaptive function. This is distinct from the earlier IQ-based qualification pathway under 12.05 or 12.11.
• Guardianship or supported decision-making. An adult who previously managed their own affairs may need formal legal support structures — representative payee for Social Security benefits, a healthcare proxy, or full guardianship — if psychosis significantly impairs decision-making capacity.
• SNT activation or establishment. A family that did not establish an SNT while the child was functioning independently must establish one at this point if significant assets are involved. A first-party (d4A) SNT is required if assets are in the individual's name; a third-party SNT can be funded by family resources.
• Antipsychotic medication costs. Second-generation antipsychotics used in schizophrenia treatment range from a few hundred to several thousand dollars per month, depending on the medication, formulation (oral vs. long-acting injectable), and insurance coverage. Clozapine, which is used in treatment-resistant schizophrenia, requires mandatory blood monitoring through REMS programs, adding ongoing laboratory costs.
• Psychiatric hospitalization reserve. First-episode psychosis frequently requires inpatient stabilization. Subsequent hospitalizations — if psychosis is poorly controlled — are a recurring cost that the SNT distribution language should explicitly authorize.

SNT distribution language for the psychiatric contingency

For 22q11.2 families, the SNT should explicitly authorize the following psychiatric expense categories, even if the beneficiary is currently asymptomatic:

• Antipsychotic medications, including long-acting injectable formulations and brand-name drugs not covered by Medicaid's preferred drug list
• Psychiatric hospitalizations, including out-of-network facilities or specialized first-episode psychosis programs
• Outpatient psychiatric care and psychotherapy
• Neuropsychological testing (needed periodically to assess cognitive functioning in schizophrenia)
• Supported employment or vocational rehabilitation if psychosis affects employment capacity
• Assisted living or supervised housing if independent living is no longer safe
• Coordination with ACT (Assertive Community Treatment) teams or similar intensive outpatient psychiatric programs

A trustee who has only generic "supplemental needs" language and receives a call about a beneficiary in psychiatric crisis may hesitate about which expenses are authorized. Explicit language removes that hesitation and ensures treatment is not delayed while the trustee seeks legal guidance.

Inheritance and GINA: the parent insurance problem

Approximately 90 to 93 percent of 22q11.2 deletions are de novo — arising spontaneously without being inherited from either parent, who typically have normal chromosomes.² In the remaining 7 to 10 percent of cases, the deletion is inherited from a parent who also carries the 22q11.2 deletion. Inheritance is autosomal dominant with 50% transmission probability — a parent with a 22q11.2 deletion has a 50% chance of passing it to each child. Importantly, the parent may be mildly affected or phenotypically near-normal, because 22q11.2 DS has highly variable expressivity even within families.

GINA's critical gap

The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from using genetic information to discriminate. However, GINA explicitly does not cover life insurance, disability income insurance, or long-term care insurance.⁵ Life and disability insurers are legally permitted to request genetic test results and use them to deny coverage, apply rated premiums, or limit benefits.

For 22q11.2 families with an inherited deletion, this creates an urgent planning sequence: if a parent suspects or has been told they may carry the 22q11.2 deletion (for example, after a child is diagnosed and the clinical geneticist offers parental testing), the parent should review and, if necessary, purchase additional life insurance and long-term disability coverage before genetic testing results appear in the medical record. A positive parental test — confirming the parent also carries the deletion — creates a documented genetic condition that life and disability insurers can use to decline coverage or charge significantly higher premiums.

This is not an argument against genetic testing for parents — understanding the inheritance pattern is valuable for family planning and the parent's own medical management. It is an argument for sequencing: consult with an insurance broker and secure any needed coverage first, then complete the parental testing. Some states have passed laws providing additional genetic privacy protections in certain insurance markets; consult a local insurance specialist to understand the rules in your state.

SSI qualification: Blue Book pathways without a CAL fast-track

22q11.2 deletion syndrome is not included on SSA's Compassionate Allowances program, which means there is no expedited 10-day processing pathway.⁴ Disability evaluation follows the standard 3 to 6 month process under the Blue Book Listing of Impairments. The appropriate Blue Book pathway depends on the individual's specific functional profile:

Listing 12.05 — Intellectual Disorder

For individuals with 22q11.2 DS who have a full-scale IQ below 70 and significant deficits in adaptive functioning (conceptual, social, or practical skills), Listing 12.05 is the most direct qualification pathway. SSA requires documentation of IQ testing, adaptive function assessment, and evidence that the intellectual impairment manifested before age 22. Because 22q11.2 DS is congenital, the onset timing is not in dispute — establishing that current IQ and adaptive deficits meet the listing criteria is the primary task.

Listing 12.11 — Neurodevelopmental Disorders

For individuals whose IQ is in the borderline range (70–85) but who have significant functional limitations due to ADHD, learning disabilities, or social cognitive deficits associated with 22q11.2 DS, Listing 12.11 may apply. The listing requires either extreme limitation in one area of mental functioning or marked limitation in two. For a 22q11.2 adult with borderline IQ, processing speed deficits, and significant social interaction limitations, marked impairment in concentration/persistence and social interaction is often documentable with neuropsychological testing.

Listing 12.03 — Schizophrenia Spectrum Disorders

If schizophrenia has developed, Listing 12.03 applies. SSA requires documented delusions, hallucinations, or disorganized speech or behavior, plus either extreme limitation in one area of mental functioning or marked limitation in two, or a medically documented history of two years of schizophrenia-related chronic mental disorder. For 22q11.2-associated schizophrenia, the genetic condition provides strong documentation of the biological basis; the psychiatric team's records establish the functional impact.

RFC (Residual Functional Capacity) approach for higher-functioning adults

For adults with 22q11.2 DS whose IQ is above 70 but who cannot sustain full-time competitive employment due to a combination of learning disabilities, processing speed deficits, psychiatric symptoms, and social difficulties, an RFC assessment may establish disability even without meeting a specific listing. This approach requires detailed vocational evidence — letters from employers, records of accommodations tried, documentation of job losses attributable to 22q11.2-related symptoms. A disability attorney with special needs experience can help assemble this case.

Age-18 SSI transition: the parental deeming cliff

For children under 18 whose parents have above-poverty income, parental income deeming typically prevents SSI eligibility during childhood — but this deeming ends on the child's 18th birthday. At age 18, the child's SSI eligibility is evaluated based solely on the child's own income and resources, not the parents'. This deeming cliff means that many 22q11.2 adolescents who were ineligible for SSI as children become eligible on their 18th birthday. Apply for SSI 3 months before the 18th birthday to time the determination correctly and avoid a gap in coverage. See the Age-18 Financial Planning Checklist for the complete transition checklist.

SSI benefit and Medicaid linkage

SSI pays up to $994 per month in 2026 (the Federal Benefit Rate).⁶ The countable resource limit is $2,000 — any inheritance, gift, or settlement received directly by the individual destroys SSI eligibility until the excess is spent down. SSI enrollment in most states automatically triggers Medicaid eligibility, which covers psychiatric medications, outpatient mental health services, and, critically, inpatient psychiatric hospitalization. For 22q11.2 families who know there is a 25–30% chance the individual will need intensive psychiatric services someday, Medicaid is not an administrative detail — it is the financing mechanism for that care.

Cardiac surgical reserves: planning for adult CHD reoperation

Approximately 75% of individuals with 22q11.2 DS are born with congenital heart disease, and most undergo one or more cardiac surgeries in infancy or early childhood.⁷ While many 22q11.2 adults with repaired CHD lead healthy lives, adult congenital heart disease carries a significant burden of late complications requiring reoperation, catheter-based intervention, or transplant evaluation.

The SNT should explicitly authorize cardiac monitoring (cardiology appointments, echocardiography, cardiac MRI, Holter monitoring), catheter-based interventions, and cardiac surgery or valve replacement. The SNT is not required to fund initial childhood surgeries — those are funded by family resources and insurance — but the trust should be structured to handle the adult cardiac reoperation risk that a 22q11.2 individual may face at age 35, 45, or 55, at a time when the parents may no longer be living.

An SNT that plans for the psychiatric contingency but not the cardiac one is only half-constructed. Both risks are real and well-documented; both should be funded.

Speech therapy and VPI surgical reserves

Velopharyngeal insufficiency (VPI) — the incomplete closure of the soft palate against the back of the throat during speech — affects approximately 70–75% of individuals with 22q11.2 DS and causes the distinctive hypernasal speech quality associated with the condition. VPI treatment involves intensive, ongoing speech therapy and in many cases surgical intervention (posterior pharyngeal flap or sphincter pharyngoplasty), typically performed between ages 3 and 7 but sometimes repeated or revised in adolescence or adulthood.

Speech therapy for VPI typically requires 2 to 3 sessions per week for years and is partially covered by insurance, with co-pays and out-of-network costs accumulating significantly over time. VPI surgery typically costs $30,000–$80,000, and speech therapy following surgery adds additional expense. The SNT distribution language should explicitly authorize speech-language pathology services for VPI, VPI surgical revision, augmentative communication tools, and voice therapy. Many 22q11.2 adults benefit from continued speech support through young adulthood; the trust should not assume this need ends with childhood.

Immune deficiency and IVIG costs

Thymic hypoplasia in 22q11.2 DS produces T-cell deficiency ranging from mild (most individuals, with normal immunological function in daily life) to complete DiGeorge syndrome (approximately 1–2% of cases, in which T-cells are absent and IVIG replacement or bone marrow transplant is required). The majority of 22q11.2 individuals have partial T-cell deficiency that does not require active treatment but may result in more frequent or more severe infections, slower recovery from illness, and lower vaccine response.

For the small minority who require ongoing IVIG infusions, costs run $20,000 to $60,000 per year, depending on body weight, dosing frequency, and infusion setting (home vs. infusion center). Medicaid typically covers IVIG for this indication; however, Medicaid coverage can be interrupted by changes in eligibility or formulary policy. The SNT should authorize IVIG and subcutaneous immunoglobulin (SCIG) infusion costs for 22q11.2 individuals with documented immune deficiency.

ABLE accounts for working 22q11.2 adults

22q11.2 deletion syndrome is an eligible diagnosis for an ABLE account in 2026: eligibility requires disability onset before age 46, and 22q11.2 DS is congenital.⁶ The annual ABLE contribution limit is $20,000 from all sources in 2026. ABLE account balances up to $100,000 are excluded from SSI's $2,000 resource limit.

For 22q11.2 adults who are working — and many higher-functioning individuals with 22q11.2 DS do work, particularly in supported employment or accommodated settings — the ABLE account serves several critical functions:

• Section 1619(b) Medicaid protection. An individual who earns above the SSI payment level ($994/month) can continue receiving Medicaid under Section 1619(b) as long as their income remains below the state's 1619(b) threshold (varies by state, typically $20,000–$55,000/year). This Medicaid coverage is essential if the individual ever needs psychiatric medication, inpatient care, or cardiac monitoring — all areas of elevated 22q11.2 risk. ABLE account balances do not affect 1619(b) eligibility.
• ABLE to Work provision. A 22q11.2 adult who is employed can contribute an additional $15,650 above the standard ABLE limit in 2026 — a total of $35,650 per year — equal to the Substantial Gainful Activity threshold.⁶ This provision enables meaningful savings growth for working beneficiaries.
• Flexible access for recurring expenses. Therapy co-pays, medication co-pays, accessible transportation, assistive technology, and other recurring qualified disability expenses can be paid directly from the ABLE account by the account holder or authorized individual, without going through the SNT trustee process.

For 22q11.2 adults who are currently functioning independently, the ABLE account is often the appropriate primary financial planning tool — simpler and more flexible than an SNT for a working individual with moderate functional limitations. The SNT becomes more important if the person receives a substantial inheritance or if their functioning declines due to psychiatric or cardiac causes. Both accounts can and should coexist; the SNT holds larger assets and handles major expenses, while the ABLE account handles day-to-day disability-related costs.

SNT structure and sizing

Third-party SNT: for family gifts and bequests

A third-party SNT, established with family assets (parents' estate plan, grandparents' gifts, life insurance), is the correct vehicle for all family resources directed toward a 22q11.2 beneficiary's care. The trust holds assets without counting toward the SSI resource limit. No Medicaid payback provision is required; assets remaining at death pass to named heirs. See the First-Party vs Third-Party SNT guide for the structural comparison.

First-party SNT: for assets received directly by the individual

If a 22q11.2 adult receives money in their own name — through inheritance from a relative who did not use an SNT in their estate plan, a personal injury settlement, or any direct receipt — a first-party (d4A) SNT can protect those assets. First-party SNTs require a Medicaid payback clause and must be established before age 65. For 22q11.2 families, first-party SNTs may also be relevant if a parent with an inherited 22q11.2 deletion passes assets to a child without proper SNT structuring.

SNT sizing for 22q11.2 deletion syndrome

SNT sizing for 22q11.2 DS is complicated by the bimodal planning scenario: the higher-functioning trajectory versus the psychiatric trajectory. The table below models the most common scenarios over a 50-year planning horizon.

The key insight for 22q11.2 families is to size the trust for the moderate-plus-psychiatric-contingency scenario, even if the child is currently functioning at the higher end. A trust sized only for the higher-functioning scenario provides false security: if schizophrenia develops and the trust has only $300,000 remaining at that point, the family faces a crisis. Sizing the trust with a psychiatric contingency reserve ensures that the financial infrastructure is already in place regardless of which trajectory the individual follows.

Use the Lifetime Care Cost Projection Calculator and the SNT Funding Calculator to model specific scenarios. A fee-only special needs financial advisor familiar with 22q11.2 DS can integrate the cardiac, psychiatric, and functional trajectories into a single coherent plan.

HCBS Medicaid waiver and the IQ-waiver type mismatch

For 22q11.2 adults who will need residential or day program support, HCBS Medicaid waivers are the primary public funding mechanism. However, the waiver type matters: most states operate separate waivers for individuals with intellectual disability (the DD/ID waiver, which funds supported living, group homes, and day habilitation) and for individuals with physical disabilities (which funds personal care aides and home modifications).

22q11.2 adults with formal intellectual disability (IQ below 70) typically qualify for the DD/ID waiver, which covers the broadest range of residential and day services. Those with borderline IQ (70–85) and primarily psychiatric disability may qualify for mental health-specific waivers in some states. The distinction is important: the DD waiver generally provides more comprehensive residential support. Families should apply for the DD waiver as early as possible if intellectual disability is present, as waitlists run 5 to 15 years in most states.⁸ See the HCBS Medicaid Waiver guide for state-specific guidance.

Guardianship vs. supported decision-making

The appropriate legal decision-making structure for a 22q11.2 adult depends significantly on their functional level and trajectory. Unlike conditions such as Angelman syndrome or Rett syndrome, which typically involve severe intellectual disability from birth, 22q11.2 DS spans a wide range of functional capacity:

• Higher-functioning adults (IQ 75–85, competitive or supported employment): Formal guardianship is often not necessary or appropriate. A supported decision-making agreement, financial power of attorney, and healthcare proxy may be sufficient to provide support while preserving autonomy. If schizophrenia later impairs capacity, a guardianship petition can be filed at that time.
• Adults with intellectual disability (IQ below 70): Limited or full guardianship of the person is typically appropriate at age 18, depending on the extent of adaptive deficits. The guardianship order should name successor guardians to ensure continuity if parents become incapacitated.
• Adults who develop schizophrenia: Capacity fluctuates with psychotic episodes. A psychiatric advance directive, established during a stable period, documents the individual's treatment preferences for periods of incapacity. This can reduce the need for formal guardianship in some cases, though full guardianship may ultimately be necessary if psychosis becomes chronic and severe.

See the Guardianship vs Supported Decision-Making guide for the full analysis of each approach. See the Age-18 Financial Checklist for the filing timeline.

Priority actions for 22q11.2 families

1. If the deletion appears inherited from a parent, review life and disability insurance immediately. Do not complete parental genetic testing until you have reviewed your life and disability insurance coverage with a broker and added any needed coverage. GINA does not protect you from life or LTD insurer discrimination. Once the parent's diagnosis is in the medical record, underwriting options narrow.
2. Apply for SSI before or at age 18. For children with 22q11.2 DS who have intellectual disability or significant functional limitations, apply 3 months before the 18th birthday. The parental deeming shift creates eligibility that may not have existed before 18. SSI establishes Medicaid — the critical access mechanism for psychiatric care if schizophrenia develops.
3. Apply for the HCBS DD waiver now if intellectual disability is present. Waitlists run 5–15 years. Every year of delay is a year the adult may spend without funded residential support after IDEA school services end at age 21. Apply now, regardless of whether services are immediately needed.
4. Establish a third-party SNT with schizophrenia-contingency language. Work with a special needs planning attorney to include explicit distribution authorization for psychiatric medications, hospitalization, supervised housing, and neuropsychological testing. Structure the trust to handle both the current functional trajectory and the psychiatric contingency without requiring an emergency amendment.
5. Include a cardiac reoperation reserve in the SNT funding target. If the individual has a history of conotruncal heart defects, add $150,000–$200,000 to the trust target for adult cardiac reoperation that may occur decades from now. Model the full target with the SNT Funding Calculator.
6. Open an ABLE account for working 22q11.2 adults. For adults who are employed, the ABLE account provides Section 1619(b) Medicaid protection, tax-advantaged savings, and flexible access for recurring disability expenses. Contribution up to $35,650/year if employed.
7. Audit all beneficiary designations and retirement accounts. Any IRA, 401(k), life insurance, or payable-on-death account naming the 22q11.2 individual directly — rather than the SNT — destroys SSI and Medicaid eligibility upon your death. Replace direct designations with designations to the SNT. See the Retirement Accounts and Special Needs guide.
8. Start and update the letter of intent. The letter of intent tells future trustees, caregivers, and guardians what your child's medical history, communication preferences, behavioral patterns, and life goals look like. For 22q11.2, document the psychiatric monitoring history, cardiac follow-up schedule, calcium supplementation regimen, and speech therapy needs. Update annually. See the Letter of Intent Template and Guide.
9. Work with a fee-only special needs advisor. The intersection of psychiatric risk, cardiac history, GINA insurance planning, and ABLE account strategy creates a financial picture that requires advisor experience with 22q11.2-specific issues. A generalist who has never modeled the schizophrenia contingency will undersize the trust and underplan the insurance.

Sources

1. 22q11.2 Deletion Syndrome — GeneReviews®, NCBI Bookshelf, NIH. 22q11.2 deletion syndrome is caused by a deletion at chromosomal band 22q11.2, most commonly a 3 Mb deletion of approximately 30–40 genes. Prevalence approximately 1 in 4,000 live births; one of the most common microdeletion syndromes and the most common multisystem malformation syndrome in humans. Clinical features include congenital heart disease (~75%), palatal anomalies (~75%), immune deficiency, hypocalcemia, and learning disabilities with average IQ approximately 70. Psychiatric disorders, including schizophrenia, are major features in adulthood.
2. Variance of IQ is Partially Dependent on Deletion Type Among 1,427 22q11.2 Deletion Syndrome Subjects — PMC, NIH (McDonald-McGinn et al.) Average full-scale IQ approximately 70; range approximately 55–85. Formal intellectual disability (IQ below 70) present in approximately 40% of individuals. Median FSIQ in de novo deletions: 77 (range 50–116); median FSIQ in inherited deletions: 67 (range 50–96). Approximately 90–93% of deletions are de novo; approximately 7–10% inherited from an affected parent.
3. Psychiatric Disorders in 22q11.2 Deletion Syndrome are Prevalent but Undertreated — PMC, NIH. Schizophrenia or related psychotic disorders affect 25–53% of individuals with 22q11.2 DS — compared with approximately 1% in the general population. 22q11.2 deletion is one of the largest known genetic risk factors for schizophrenia. Approximately 60% of adults with 22q11.2 DS have at least one psychiatric disorder, including anxiety disorders, depression, ADHD, OCD, and psychotic disorders. Onset of psychosis typically in late adolescence and early adulthood. The deletion is present in approximately 1–2% of all schizophrenia patients.
4. SSA — Complete List of Conditions: Compassionate Allowances. 22q11.2 deletion syndrome (DiGeorge syndrome) is not included on SSA's Compassionate Allowances list as of 2026. Standard disability evaluation under the Blue Book Listing of Impairments applies, with a typical processing time of 3 to 6 months. Applicable Blue Book listings: 12.05 (Intellectual Disorder), 12.11 (Neurodevelopmental Disorders), 12.03 (Schizophrenia Spectrum Disorders), 4.05/4.06 (cardiac arrhythmia/congenital heart disease). RFC assessment may apply for higher-functioning individuals who do not meet a specific listing.
5. National Human Genome Research Institute — Genetic Discrimination. GINA (Genetic Information Nondiscrimination Act) prohibits discrimination in health insurance and employment based on genetic information. GINA explicitly does not cover life insurance, disability income insurance, or long-term care insurance. Life and disability insurers are legally permitted to request genetic test results and to use them in underwriting decisions — including declining coverage, applying rated premiums, or limiting benefits. Some states have enacted additional protections that go beyond GINA's scope; consult a local insurance specialist for state-specific rules.
6. SSA — SSI Federal Payment Amounts 2026. SSI Federal Benefit Rate: $994/month for an eligible individual (2026). SSI countable resource limit: $2,000. SGA: $1,690/month (non-blind). Section 1619(b): SSI beneficiaries who earn above the payment level may retain Medicaid eligibility as long as income remains below the state-specific threshold. ABLE contribution limit: $20,000/year from all sources (2026). ABLE to Work additional contribution: up to $15,650 above the standard limit for employed beneficiaries (equal to 2026 SGA threshold). ABLE age eligibility: disability onset before age 46 (ABLE Age Adjustment Act, effective January 2026).
7. Congenital Heart Disease in 22q11.2 Deletion Syndrome: A Meta-Analysis and Systematic Review — PMC, NIH (2025). Pooled prevalence of CHD in 22q11.2 DS: approximately 75%. Specific defect prevalence: tetralogy of Fallot ~20%, ventricular septal defect ~14%, pulmonary atresia with VSD ~9%, interrupted aortic arch ~10%, truncus arteriosus communis ~9%, atrial septal defect ~3%. Conotruncal defects predominate. Late adult complications including pulmonary valve dysfunction in repaired TOF, recoarctation in repaired IAA, and conduit failure in truncus arteriosus repair are established risks requiring ongoing cardiology follow-up.
8. Medicaid.gov — Home and Community-Based Services (HCBS). HCBS 1915(c) waivers fund home and community-based services for individuals who would otherwise require institutional care. DD/ID waivers cover supported living, group homes, day habilitation, respite, and supported employment for individuals with intellectual and developmental disabilities, including those with 22q11.2 DS and formal intellectual disability. Physical disability waivers cover personal care and home modification for individuals whose primary disability is physical. Waitlists average 5–15 years in most states; early enrollment is critical for securing a slot before IDEA services end at age 21.

Rules verified against 2026 SSA and ABLE standards. SSI FBR $994/month; SSI resource limit $2,000; SSDI SGA $1,690/month non-blind (all 2026). ABLE contribution limit $20,000/year; ABLE to Work additional $15,650; age eligibility onset before 46 (all 2026). Clinical prevalence figures from peer-reviewed literature cited above. GINA insurance scope: federal GINA does not cover life, disability, or LTC insurance. This guide does not constitute financial, legal, tax, or insurance advice.